Background: Human immunoglobulin G (IgG) directed against Group B streptococcus (GBS) epitopes is transferred transplacentally from the mother to the fetus. A GBS putative protein, gbs2106, has been previously identified as a potential GBS protein antigen vaccine candidate. However, its genetic prevalence and surface expression in GBS-isolates has not been evaluated.
View Article and Find Full Text PDFAims: To assess functional outcomes, health-related quality-of-life (HRQoL), and satisfaction at 1-year following knee arthroplasty (KA) in patients aged ≥80 compared to those aged 65-75-years when adjusting for confounding factors.
Methods: A single-centre retrospective cohort study was performed using data from 2010 to 2020. Demographic data, length of stay (LOS), preoperative and 1-year postoperative EuroQol (EQ-5D and EQ-VAS), Oxford Knee Score (OKS) and Outcome Satisfaction (OS) were recorded.
Implanted neural interfaces are electronic devices that stimulate or record from neurons with the purpose of improving the quality of life of people who suffer from neural injury or disease. Devices have been designed to interact with neurons throughout the body to treat a growing variety of conditions. The development and use of implanted neural interfaces is increasing steadily and has shown great success, with implants lasting for years to decades and improving the health and quality of life of many patient populations.
View Article and Find Full Text PDFThe enzymatic synthesis of heterocycles is an emerging biotechnology for the sustainable construction of societally important molecules. Herein, we describe an enzyme-mediated strategy for the oxidative dimerization of thioamides enabled by enzymatic halide recycling by vanadium-dependent haloperoxidase enzymes. This approach allows for intermolecular biocatalytic bond formation using a catalytic quantity of halide salt and hydrogen peroxide as the terminal oxidant.
View Article and Find Full Text PDFWhether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible regardless of social determinants of health (SDOH) remains unknown. We examined associations of SDOH with access to allo-HCT and other outcomes. Patients presenting for treatment (n=692) at 13 AML treatment centers were prospectively recruited to a registered clinical trial (#NCT01929408).
View Article and Find Full Text PDF